These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24930034)

  • 1. Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator.
    Krause A; Brossard P; D'Ambrosio D; Dingemanse J
    J Pharmacokinet Pharmacodyn; 2014 Jun; 41(3):261-78. PubMed ID: 24930034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: favorable impact of dose up-titration.
    Brossard P; Scherz M; Halabi A; Maatouk H; Krause A; Dingemanse J
    J Clin Pharmacol; 2014 Feb; 54(2):179-88. PubMed ID: 24408162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study.
    Brossard P; Derendorf H; Xu J; Maatouk H; Halabi A; Dingemanse J
    Br J Clin Pharmacol; 2013 Dec; 76(6):888-96. PubMed ID: 23594176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of ponesimod and its primary metabolites in healthy and organ-impaired subjects.
    Lott D; Krause A; Dingemanse J; Lehr T
    Eur J Pharm Sci; 2016 Jun; 89():83-93. PubMed ID: 27108115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Demographics, Organ Impairment, Disease, Formulation, and Food on the Pharmacokinetics of the Selective S1P
    Lott D; Lehr T; Dingemanse J; Krause A
    Clin Pharmacokinet; 2017 Apr; 56(4):395-408. PubMed ID: 27638335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Pharmacokinetics of Ponesimod, a Selective S1P1 Receptor Modulator, in the Treatment of Multiple Sclerosis.
    Kruger TM; Valenzuela B; Thompson CD; Ouwerkerk-Mahadevan S; Ruixo JJP
    Clin Pharmacokinet; 2023 Nov; 62(11):1533-1550. PubMed ID: 37776485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ponesimod, a selective sphingosine 1-phosphate (S1P
    Dash RP; Rais R; Srinivas NR
    Xenobiotica; 2018 May; 48(5):442-451. PubMed ID: 28489480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling the Effect of the Selective S1P
    Lott D; Krause A; Seemayer CA; Strasser DS; Dingemanse J; Lehr T
    Pharm Res; 2017 Mar; 34(3):599-609. PubMed ID: 28028771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology of ponesimod, a selective S1P₁ receptor modulator, after uptitration to supratherapeutic doses in healthy subjects.
    Hoch M; D'Ambrosio D; Wilbraham D; Brossard P; Dingemanse J
    Eur J Pharm Sci; 2014 Oct; 63():147-53. PubMed ID: 25046167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitigation of Initial Cardiodynamic Effects of the S1P
    Juif PE; Hoch M; Vaclavkova A; Krause A; Bush J; Dingemanse J
    J Clin Pharmacol; 2017 Mar; 57(3):401-410. PubMed ID: 27558098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of ethnicity and sex on the pharmacokinetics and pharmacodynamics of the selective sphingosine-1-phosphate receptor 1 modulator ponesimod: a clinical study in Japanese and Caucasian subjects.
    Reyes M; Hoch M; Brossard P; Dingemanse J
    Pharmacology; 2014; 94(5-6):223-9. PubMed ID: 25402365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three different up-titration regimens of ponesimod, an S1P1 receptor modulator, in healthy subjects.
    Scherz MW; Brossard P; D'Ambrosio D; Ipek M; Dingemanse J
    J Clin Pharmacol; 2015 Jun; 55(6):688-97. PubMed ID: 25612299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Desensitization by progressive up-titration prevents first-dose effects on the heart: guinea pig study with ponesimod, a selective S1P1 receptor modulator.
    Rey M; Hess P; Clozel M; Delahaye S; Gatfield J; Nayler O; Steiner B
    PLoS One; 2013; 8(9):e74285. PubMed ID: 24069292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of ponesimod, a selective S1P1 receptor modulator, on blood-circulating human T cell subpopulations.
    D'Ambrosio D; Steinmann J; Brossard P; Dingemanse J
    Immunopharmacol Immunotoxicol; 2015 Feb; 37(1):103-9. PubMed ID: 25519470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ponesimod, a selective S1P1 receptor modulator, on the pharmacokinetics of a hormonal combination contraceptive.
    Reyes M; Brossard P; Chassard D; Hoch M; Dingemanse J
    Eur J Clin Pharmacol; 2014 Mar; 70(3):287-93. PubMed ID: 24362488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ponesimod, a selective S1P1 receptor modulator, on the QT interval in healthy individuals.
    Hoch M; Darpo B; Brossard P; Zhou M; Stoltz R; Dingemanse J
    Basic Clin Pharmacol Toxicol; 2015 May; 116(5):429-37. PubMed ID: 25287214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling Tolerance Development for the Effect on Heart Rate of the Selective S1P
    Lott D; Lehr T; Dingemanse J; Krause A
    Clin Pharmacol Ther; 2018 Jun; 103(6):1083-1092. PubMed ID: 28913826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biocomparison of Three Formulations of the S1P1 Receptor Modulator Ponesimod in Healthy Subjects.
    Juif PE; Hoch M; D'Ambrosio D; Dingemanse J
    Drugs R D; 2015 Jun; 15(2):203-10. PubMed ID: 25939333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mass balance, pharmacokinetics and metabolism of the selective S1P1 receptor modulator ponesimod in humans.
    Reyes M; Hoch M; Brossard P; Wagner-Redeker W; Miraval T; Dingemanse J
    Xenobiotica; 2015 Feb; 45(2):139-49. PubMed ID: 25188442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absolute Bioavailability of Ponesimod, a Selective S1P
    Boehler M; Juif PE; Hoch M; Dingemanse J
    Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):129-134. PubMed ID: 26883438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.